Neuroendocrine tumor disease state and RAND-36 health-related quality of life scores

#45

Introduction: Health-related quality of life (HRQL) can be disrupted in patients with malignancies.

Aim(s): To compare the HRQL burden of patients with neuroendocrine tumors (NET) in different disease states relative to the general population.

Materials and methods: Patients with NET were invited via e-mail to participate in an online anonymous survey. The survey consisted of demographic and disease-related questions and two standardized measures of HRQL (RAND-36 and PROMIS-29). HRQL scores for the US general population are normalized to 50. RAND-36 scores were compared using analysis of variance among three groups: patients with no tumor currently present (e.g., was surgically removed)—no current NET; patients with tumor that has not been surgically removed or has come back after surgery—current NET, but without carcinoid syndrome; current NET with carcinoid syndrome. Score differences of 2.5 - 5.0 points are generally regarded as clinically meaningful. Lower scores indicate worse HRQL.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Phan A, Beaumont J, Liu Z, Choi S, Cella D,

Keywords: neuroendocrine tumor, health-related quality of life, carcinoid syndrome,